A Phase 2 interventional study of Calcium Chloride and Placebo in Post Partum Haemorrhage and Cesarean Section Surgery, sponsored by Pak Emirates Military Hospital. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Pak Emirates Military Hospital · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Postpartum Hemorrhage with a site in Pakistan — 4 open to participants now, 4 under way, none of them phase 3. Postpartum Hemorrhage · Pakistan.
Among the 17 studies in Postpartum Hemorrhage with a site in Pakistan, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, and was the 14th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →4 of the 17 studies in Postpartum Hemorrhage with a site in Pakistan are open now. Recruiting first, the newest first:
Aziz Fatimah Medical & Dental College, Faisalabad · Sites in Pakistan
Ages 18–35 · Women only
Khyber Girls Medical College · Sites in Pakistan
Ages 18–40 · Women only
Patel Hospital, Pakistan · Sites in Pakistan
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 182 is above the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 181 across the 16 interventional studies, 121 across the 1 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
Pak Emirates Military Hospital is the lead sponsor of 24 studies on the registry; 12 are open to participants now.
Pak Emirates Military Hospital has 1 study filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
3 of the studies in Postpartum Hemorrhage with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07550413Pak Emirates Military HospitalRole of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section | 2026-11 |
| NCT07845240Aziz Fatimah Medical & Dental College, FaisalabadEfficacy of Balloon Tamponade in Post-partum Hemorrhage Within 24 Hours After Delivery | 2027-04-01 |
| NCT07784478Khyber Girls Medical CollegeEffect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Postpartum Hemorrhage with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the effectiveness of prophylactic intravenous calcium chloride administered after cord clamping in reducing postpartum blood loss during intrapartum cesarean section.
After approval from the hospital's ethical review committee, written informed consent will be obtained from all participants. Baseline characteristics such as age, parity, gestational age, height, and weight for body mass index will be documented. A total of 182 women will be randomly allocated into two equal groups (91 each) using the lottery method. Group A will receive 1 g of intravenous calcium chloride diluted in 100 mL of normal saline, administered over 10 minutes beginning one minute after cord clamping, in addition to standard oxytocin therapy (10 IU intravenous bolus followed by 20 IU infusion). Group B will receive standard care with oxytocin alone.Quantitative blood loss will be calculated using the gravimetric method. All surgical swabs, drapes, and pads will be weighed immediately after use, and their pre-determined dry weights will be subtracted to obtain the net blood loss, with the assumption that 1 g of weight gain is equivalent to 1 mL of blood. Blood collected in suction containers will also be measured. Adjustment for amniotic fluid will be made by recording the volume of clear amniotic fluid suctioned immediately after uterine incision and before placental delivery, which will then be subtracted from the total suction volume. Each weighed item and suction measurement will be labeled sequentially according to the patient's study ID at the time of surgery. The labeling and confirmation will be carried out by a consultant obstetrician with more than five years of experience, in collaboration with the researcher, at the end of the procedure.All data will be recorded using a predefined proforma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A will receive 1 g of intravenous calcium chloride diluted in 100 mL of normal saline, administered over 10 minutes beginning one minute after cord clamping, in addition to standard oxytocin therapy (10 IU intravenous bolus followed by 20 IU infusion).
Drug: Calcium Chloride
Group B will receive standard care with oxytocin alone.
Other: Placebo
Group A will receive 1 g of intravenous calcium chloride diluted in 100 mL of normal saline, administered over 10 minutes beginning one minute after cord clamping, in addition to standard oxytocin therapy (10 IU intravenous bolus followed by 20 IU infusion).
Group B will receive standard care with oxytocin alone.
Blood Loss
Quantitative blood loss will be calculated using the gravimetric method. All surgical swabs, drapes, and pads will be weighed immediately after use, and their pre-determined dry weights will be subtracted to obtain the net blood loss, with the assumption that 1 g of weight gain is equivalent to 1 mL of blood. Blood collected in suction containers will also be measured. Adjustment for amniotic fluid will be made by recording the volume of clear amniotic fluid suctioned immediately after uterine incision and before placental delivery, which will then be subtracted from the total suction volume. Each weighed item and suction measurement will be labeled sequentially according to the patient's study ID at the time of surgery.
Time frame: 24 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calcium Chloride
Pak Emirates Military Hospital